For the year ending 2025-12-31, VRCA made $35,577K in revenue. -$17,886K in net income. Net profit margin of -50.27%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 35,577 | |||
| Cost of product revenue | 2,192 | |||
| Cost of license and collaboration revenue | 1,249 | |||
| Selling, general and administrative | 35,220 | |||
| Research and development | 8,855 | |||
| Loss on disposal of equipment | -246 | |||
| Total operating expenses | 47,762 | |||
| Loss from operations | -12,185 | |||
| Interest income | 929 | |||
| Interest expense | 7,742 | |||
| Change in fair value of derivative liability | 2,648 | |||
| Loss on extinguishment of debt | -1,533 | |||
| Other expense | -3 | |||
| Total other expense, net | -5,701 | |||
| Net loss | -17,886 | |||
| Basic EPS | -1.68 | |||
| Diluted EPS | -1.68 | |||
| Basic Average Shares | 10,652,367 | |||
| Diluted Average Shares | 10,652,367 | |||
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)